Prazitone
Clinical data
Other names5-phenyl-5-(2-piperidylmethyl)barbituric acid
ATC code
  • none
Identifiers
  • 5-phenyl-5-(piperidin-2-ylmethyl)pyrimidine-2,4,6(1H,3H,5H)-trione
CAS Number
PubChem CID
ChemSpider
UNII
Chemical and physical data
FormulaC16H19N3O3
Molar mass301.346 g·mol−1
3D model (JSmol)
  • C1CCNC(C1)CC2(C(=O)NC(=O)NC2=O)C3=CC=CC=C3
  • InChI=1S/C16H19N3O3/c20-13-16(11-6-2-1-3-7-11,14(21)19-15(22)18-13)10-12-8-4-5-9-17-12/h1-3,6-7,12,17H,4-5,8-10H2,(H2,18,19,20,21,22) ☒N
  • Key:UGZAKKMLMJITLL-UHFFFAOYSA-N ☒N
 ☒NcheckY (what is this?)  (verify)

Prazitone (AGN-511) is a barbiturate derivative developed in the 1970s.[1] Unlike most barbiturates, it has little or no sedative effects, instead acting as a non-sedating anxiolytic and antidepressant.[2] The dosage range in humans is around 200–600 mg, although higher doses have been used in trials for the treatment of depression associated with Parkinson's disease.

References

  1. ^ DE Patent 1645911
  2. ^ Ross Langlands. Method for imparting anti-depressant and/or anxiolytic effects to animals. US Patent 3,806,596


Categories